Technical Analysis for MNK - Mallinckrodt plc

Grade Last Price % Change Price Change
grade F 1.57 1.95% 0.03
MNK closed up 1.95 percent on Thursday, August 6, 2020, on 83 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical MNK trend table...

Date Alert Name Type % Chg
Bullish Engulfing Bullish 0.00%
Calm After Storm Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Calm After Storm Range Contraction 1.95%
Lower Bollinger Band Walk Weakness 1.95%
Stochastic Reached Oversold Weakness 1.95%
Earnings Movers Other 1.95%
Wide Bands Range Expansion 1.95%
Below Lower BB Weakness 1.95%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Mallinckrodt public limited company develops, manufactures, markets, and distributes branded and generic specialty pharmaceuticals, active pharmaceutical ingredients (API), and diagnostic imaging agents worldwide. The company's Specialty Pharmaceuticals segment offers EXALGO extended-release tablets to treat pain in opioid-tolerant patients; and GABLOFEN injections indicated for use in the management of spasticity of cerebral or spinal origin in patients age four years and above. This segment also provides generic drugs, such as oxycodone or in combination with acetaminophen, as well as hydrocodone, which in combination with acetaminophen to treat pain; and methylphenidate to treat attention deficit hyperactivity disorder. This segment markets its branded products to physicians, including pain specialists, anesthesiologists, orthopedic surgeons, rheumatologists, and neurologists; and generic products to wholesalers, large- and medium-sized retail pharmacy chains, food store chains with pharmacies, mail order pharmacies, and other channels of distribution. Its Global Medical Imaging segment provides contrast media and delivery systems comprising iodine- and gadolinium-containing injectable products for diagnostic imaging applications, such as computed tomography and magnetic resonance imaging under the Optiray and Optimark brand names. This segment also offers nuclear imaging agents consisting of Technescan MAG3, a nuclear imaging agent to detect and evaluate a range of renal disorders; technetium-99m for use in Ultra-Technekow DTE generators; cold kits; and other radiopharmaceuticals, such as Octreoscan to detect cancer. This segment sells its contrast media systems to hospitals and hospital groups; branded products directly to managed care organizations; and API products to other pharmaceutical companies. The company was incorporated in 2013 and is based in Dublin, Ireland. Mallinckrodt plc (NYSE:MNK) operates independently of Covidien plc as of June 28, 2013.
Medicine Cancer Physical Sciences Pharmaceutical Pain Natural Sciences Medical Imaging Diagnostic Imaging Medical Physics Active Pharmaceutical Ingredients Magnetic Resonance Imaging Tomography Attention Deficit Hyperactivity Disorder Radiopharmaceuticals Medicinal Radiochemistry Contrast Media Covidien Generic Products Radiochemistry Renal Disorders

Is MNK a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 6.42
52 Week Low 1.0
Average Volume 5,746,432
200-Day Moving Average 3.24
50-Day Moving Average 2.55
20-Day Moving Average 2.32
10-Day Moving Average 1.98
Average True Range 0.28
ADX 17.41
+DI 21.00
-DI 35.08
Chandelier Exit (Long, 3 ATRs ) 2.35
Chandelier Exit (Short, 3 ATRs ) 2.21
Upper Bollinger Band 3.18
Lower Bollinger Band 1.46
Percent B (%b) 0.06
BandWidth 74.19
MACD Line -0.25
MACD Signal Line -0.18
MACD Histogram -0.0772
Fundamentals Value
Market Cap 152.35 Million
Num Shares 97 Million
EPS -4.63
Price-to-Earnings (P/E) Ratio -0.34
Price-to-Sales 0.92
Price-to-Book 0.59
PEG Ratio 0.79
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.80
Resistance 3 (R3) 1.79 1.72 1.76
Resistance 2 (R2) 1.72 1.66 1.72 1.74
Resistance 1 (R1) 1.64 1.62 1.68 1.65 1.73
Pivot Point 1.57 1.57 1.59 1.57 1.57
Support 1 (S1) 1.49 1.51 1.53 1.50 1.41
Support 2 (S2) 1.42 1.47 1.42 1.40
Support 3 (S3) 1.34 1.42 1.38
Support 4 (S4) 1.35